You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MEK Inhibitor-Associated Serous Retinopathy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MEK Inhibitor-Associated Serous Retinopathy Trial in Paris (OCT-B scan)

Recruiting
  • MEK Inhibitor-Associated Serous Retinopathy
  • OCT-B scan
  • Paris, France
    Fondation A de Rothschild
Jan 24, 2022

Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer Trial in Oklahoma City (VS-6766 + defactinib)

Not yet recruiting
  • Endometrioid Cancer
  • +3 more
  • VS-6766 + defactinib
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
Aug 19, 2022

NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma Trial in United Kingdom (VS-6766, Defactinib)

Recruiting
  • NSCLC
  • +3 more
  • Manchester, Greater Manchester, United Kingdom
  • +4 more
Mar 18, 2022

Ovarian Cancer Trial in Worldwide (VS-6766, VS-6766 and Defactinib)

Recruiting
  • Low Grade Ovarian Serous Adenocarcinoma
  • Ovarian Cancer
  • avutometinib (VS-6766)
  • avutometinib (VS-6766) and Defactinib
  • Scottsdale, Arizona
  • +46 more
Dec 29, 2022

Neurofibromatosis Type 1, Plexiform Neurofibroma, Optic Nerve Glioma Trial in London (Selumetinib)

Recruiting
  • Neurofibromatosis Type 1
  • +2 more
  • London, United Kingdom
  • +1 more
Nov 11, 2021

Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Tumor, Other MAP-K Pathway Driven Diseases Trial

Available
  • Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
  • +2 more
  • Mirdametinib (MEK Inhibitor)
  • (no location specified)
Aug 24, 2021

Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) Trial in United States (Mirdametinib (PD-0325901) oral capsule or

Active, not recruiting
  • Plexiform Neurofibroma
  • Neurofibromatosis Type 1 (NF1)
  • Mirdametinib (PD-0325901) oral capsule or dispersible tablet
  • Birmingham, Alabama
  • +49 more
Nov 17, 2022

BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

Terminated
  • BRAF V600E Mutation Present
  • +7 more
  • Boston, Massachusetts
  • +1 more
Mar 9, 2022

Malignant Solid Tumor, Ovarian Low Grade Serous Adenocarcinoma, Pancreatic Carcinoma Trial (Binimetinib, Biopsy, Biospecimen

Not yet recruiting
  • Malignant Solid Neoplasm
  • +4 more
  • (no location specified)
Nov 8, 2022

Uveal Melanoma Trial in New York, Houston (Selumetinib)

Active, not recruiting
  • Uveal Melanoma
  • New York, New York
  • +2 more
Jun 28, 2022

Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma Trial in United States

Completed
  • Endometrial Adenocarcinoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Hartford, Connecticut
  • +21 more
Oct 13, 2020

Central Serous Chorioretinopathy Trial in Bordeaux (micropulse laser)

Not yet recruiting
  • Central Serous Chorioretinopathy
  • micropulse laser
  • Bordeaux, France
    CHU Bordeaux
Jan 9, 2023

Rechallenge of BRAF +/- MEK Inhibitors FollowingAdverse Event in

Active, not recruiting
  • Cancer
  • BRAF inhibitor
  • (no location specified)
Oct 13, 2021

Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)

Active, not recruiting
  • Malignant Peripheral Nerve Sheath Tumors
  • Neurofibromatosis 1
  • Washington, District of Columbia
  • +4 more
Apr 1, 2022

High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous

Recruiting
  • High Grade Fallopian Tube Serous Adenocarcinoma
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Melanoma Trial in Boston (MCS110, Dabrafenib, Trametinib)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 14, 2022

Rosacea, Erythematotelangiectatic Trial in Albany (Trametinib)

Recruiting
  • Rosacea, Erythematotelangiectatic
  • Albany, New York
    Samuel S. Stratton VA Medical Center
Nov 9, 2022

Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma Trial in Memphis (Mirdametinib)

Recruiting
  • Low-Grade Glioma
  • +2 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Oct 24, 2022

Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1
  • Neurofibroma Plexiform
  • Shanghai, China
  • +1 more
Jan 13, 2023

Anaplastic Thyroid Cancer Trial in Leiden (dabrafenib/trametinib)

Recruiting
  • Anaplastic Thyroid Cancer
  • Leiden, Zuid-Holland, Netherlands
    Ellen Kapiteijn
Oct 5, 2023

Neurofibromatosis Type 1, Plexiform Neurofibroma Trial in United States (Binimetinib)

Active, not recruiting
  • Neurofibromatosis Type 1
  • Plexiform Neurofibroma
  • Birmingham, Alabama
  • +21 more
Dec 4, 2021

Low Grade Serous Carcinoma Trial in United States (Ribociclib, Letrozole)

Recruiting
  • Low Grade Serous Carcinoma
  • San Francisco, California
  • +26 more
Feb 15, 2022

Healthy Trial in Neu-Ulm (ATR-002, Placebo, Repaglinide)

Recruiting
  • Healthy
  • Neu-Ulm, Germany
    Atriva study site
Sep 22, 2022

Uterine Serous Carcinoma Trial in Worldwide (Adavosertib)

Active, not recruiting
  • Uterine Serous Carcinoma
  • Burbank, California
  • +26 more
Jan 10, 2023

Melanoma Trial in Boston, Harrison, New York (Dabrafenib, Trametinib, Phenformin)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
  • +2 more
Jun 14, 2022